Diclofenac Potassium Patent Expiration
Diclofenac Potassium is Used for relief of mild to moderate acute pain as a nonsteroidal anti-inflammatory drug. It was first introduced by Novartis Pharmaceuticals Corp
Diclofenac Potassium Patents
Given below is the list of patents protecting Diclofenac Potassium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zipsor | US7662858 | Method of treating post-surgical acute pain | Feb 24, 2029 | Assertio Speclty |
| Zipsor | US7884095 | Method of treating post-surgical acute pain | Feb 24, 2029 | Assertio Speclty |
| Zipsor | US7939518 | Method of treating post-surgical acute pain | Feb 24, 2029 | Assertio Speclty |
| Zipsor | US8110606 | Method of treating post-surgical acute pain | Feb 24, 2029 | Assertio Speclty |
| Zipsor | US8623920 | Method of treating post-surgical acute pain | Feb 24, 2029 | Assertio Speclty |
| Zipsor | US9561200 | Method of treating post-surgical acute pain | Feb 24, 2029 | Assertio Speclty |
| Cambia | US7759394 | Diclofenac formulations and methods of use | Jun 16, 2026 | Assertio Speclty |
| Cambia | US8097651 | Diclofenac formulations and methods of use | Jun 16, 2026 | Assertio Speclty |
| Cambia | US8927604 | Diclofenac formulations and methods of use | Jun 16, 2026 | Assertio Speclty |
| Cambia | US9827197 | Diclofenac formulations and methods of use | Jun 16, 2026 | Assertio Speclty |
| Zipsor | US6365180 | Oral liquid compositions |
Jul 15, 2019
(Expired) | Assertio Speclty |
| Zipsor | US6287594 | Oral liquid compositions |
Jan 15, 2019
(Expired) | Assertio Speclty |
| Cambia | US6974595 | Pharmaceutical compositions based on Diclofenae |
May 15, 2017
(Expired) | Assertio Speclty |
| Cambia | US7482377 | Pharmaceutical compositions and methods of treatment based on diclofenac |
May 15, 2017
(Expired) | Assertio Speclty |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Diclofenac Potassium's patents.
Latest Legal Activities on Diclofenac Potassium's Patents
Given below is the list recent legal activities going on the following patents of Diclofenac Potassium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Aug, 2024 | US9561200 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Large Entity | 29 Aug, 2024 | US9561200 |
| Application ready for PDX access by participating foreign offices | 29 May, 2024 | US7939518 |
| Application ready for PDX access by participating foreign offices | 24 May, 2024 | US7662858 |
| Application ready for PDX access by participating foreign offices | 15 May, 2024 | US7884095 |
| Application ready for PDX access by participating foreign offices | 15 May, 2024 | US8110606 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Aug, 2023 | US8110606 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Nov, 2022 | US7939518 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Aug, 2022 | US7884095 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Aug, 2021 | US7662858 |
Diclofenac Potassium's Family Patents
